The FDA announced it will review a resubmitted supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
Nuplazid (pimavanserin, Acadia Pharmaceuticals) is a selective serotonin inverse agonist and antagonist that targets 5-HT2A receptors, which are thought to play an important role in neuropsychiatric